Literature DB >> 29524105

Author Correction to: Denosumab: A Review in Postmenopausal Osteoporosis.

Emma D Deeks1.   

Abstract

In the original publication the name of the fourth reviewer was incorrectly published.

Entities:  

Year:  2018        PMID： 29524105     DOI： 10.1007/s40266-018-0535-5

Source DB:  PubMed          Journal:  Drugs Aging        ISSN： 1170-229X            Impact factor:   3.923


  4 in total

Review 1.  Pros and Cons of Denosumab Treatment for Osteoporosis and Implication for RANKL Aptamer Therapy.

Authors:  Ning Zhang; Zong-Kang Zhang; Yuanyuan Yu; Zhenjian Zhuo; Ge Zhang; Bao-Ting Zhang
Journal:  Front Cell Dev Biol       Date:  2020-05-14

2.  The Skeletal Effects of Tanshinones: A Review.

Authors:  Sophia Ogechi Ekeuku; Kok-Lun Pang; Kok-Yong Chin
Journal:  Molecules       Date:  2021-04-16       Impact factor: 4.411

3.  Pharmacokinetics, Pharmacodynamics, Safety and Immunogenicity of CMAB807, a New Denosumab Biosimilar, in Healthy Chinese Subjects.

Authors:  Hanjing Chen; Weili Chen; Fei Yuan; Qingcheng Guo; Xunmin Zhang; Chenguang Wang; Xuening Li
Journal:  Front Pharmacol       Date:  2022-01-24       Impact factor: 5.810

4.  Low Serum Levels of Soluble Receptor Activator of Nuclear Factor κ B Ligand (sRANKL) Are Associated with Metabolic Dysregulation and Predict Long-Term Mortality in Critically Ill Patients.

Authors:  Tobias Puengel; Beate Weber; Theresa H Wirtz; Lukas Buendgens; Sven H Loosen; Lukas Geisler; Burcin Özdirik; Karim Hamesch; Samira Abu Jhaisha; Jonathan F Brozat; Philipp Hohlstein; Albrecht Eisert; Eray Yagmur; Christian Trautwein; Frank Tacke; Alexander Koch
Journal:  Diagnostics (Basel)       Date:  2021-12-28
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.